Business
KRTL Holding Group, Inc. Announces Exclusive Distribution and Commercialization Agreement With Star Pharmaceuticals
KRTL Holding Group, Inc. Announces Exclusive Distribution and Commercialization Agreement With Star Pharmaceuticals.
About this update from Krtl Holding Group, Inc
[{"type":"text","content":"KRTL Holding Group, Inc. (OTC: KRTL)\r\n(“KRTL” or the “Company”), today announced that its wholly owned subsidiary,\r\nKRTL Biotech, Inc. (“KRTL Biotech”), has entered into a Distribution, Supply\r\nand Promotion Agreement with Star Pharmaceuticals, LLC (“STAR”). Under the\r\nterms of the arrangement, KRTL Biotech obtained exclusive rights, subject to\r\nperformance requirements, to commercialize, distribute, and promote certain\r\nnon-prescription formulations within the United States, Central America, South\r\nAmerica, the Caribbean, and Thailand. The arrangement has an initial five-year\r\nterm and includes a revenue-sharing structure tied to net sales.\r\nThis strategic collaboration\r\npositions KRTL Biotech within a growing segment of the broader health and\r\nwellness and specialty product markets, where demand for differentiated\r\nformulations, alternative delivery formats, and internationally scalable distribution\r\nplatforms continues to evolve. The Company believes this structure enables\r\nparticipation in emerging product categories while maintaining a disciplined,\r\ncompliance-first operating model.\r\nThe framework also provides for KRTL\r\nBiotech to oversee regulatory coordination, market development, distribution,\r\nand promotional activities, while utilizing third-party manufacturing partners\r\noperating under applicable current Good Manufacturing Practice (cGMP)\r\nstandards. STAR will contribute product-related intellectual property and\r\ntechnical support under an exclusive license within the defined field.\r\n“This represents a disciplined but\r\nimportant expansion of our commercial strategy,” said Cesar Herrera, CEO of\r\nKRTL Holding Group and KRTL Biotech. “We are entering a category that continues\r\nto attract market interest, while applying a controlled approach centered on\r\nregulatory alignment, supply chain structure, and scalable distribution.”\r\nMethylene blue and related compounds\r\nhave a long history of use across medical and research settings and are now\r\nseeing renewed commercial interest within broader health and specialty product\r\nmarkets. The Company believes evolving consumer awareness, new delivery\r\nformats, and expanding global distribution channels are contributing to\r\nincreasing market attention, subject to applicable regulatory frameworks.\r\nThe collaboration is...